Hydrogel Peptide Delivery: Slow-Release Injectable Gels
Peptide Delivery Systems
3 months
Self-assembling peptide hydrogels sustained antibody release for three months in vitro, demonstrating the extended delivery window these systems can achieve.
Koutsopoulos et al., Journal of Controlled Release, 2012
Koutsopoulos et al., Journal of Controlled Release, 2012
View as imageMost peptide drugs are cleared from the body within hours. A single injection of a therapeutic peptide produces a sharp spike in blood concentration followed by rapid decline, requiring frequent dosing that reduces patient compliance and creates wasteful peak-trough pharmacokinetics. Injectable hydrogels solve this by trapping peptides within a three-dimensional gel network at the injection site, releasing them gradually as the gel degrades or the peptide diffuses out. Koutsopoulos et al. (2012) demonstrated that two-layered self-assembling peptide hydrogels could sustain antibody release for three months, showing the range of delivery timelines these systems can achieve.[1] For a broader overview of peptide delivery systems including liposomal approaches, see our pillar article.
Key Takeaways
- Self-assembling peptide hydrogels form nanofiber scaffolds that sustained antibody release for 3 months in vitro, with release kinetics controllable by peptide concentration and layering (Koutsopoulos et al., 2012)
- Temperature-responsive hydrogels are injectable as liquids at room temperature and gel at body temperature, creating a depot that releases antimicrobial peptides while simultaneously controlling infection (Bai et al., 2026)
- Charge-complementary peptide hydrogels achieved sustained release of antimicrobial peptides over 14+ days for periodontitis treatment, reducing both bacteria and bone loss (Chen et al., 2026)
- Nanoparticle-hydrogel combinations for ocular delivery sustained anti-VEGF peptide release, reducing the need for repeated intraocular injections (Durak et al., 2026)
- Self-healing hydrogels loaded with LL-37 derivatives combined infection control with wound healing in a single injectable formulation (Ba et al., 2026)
What Makes Hydrogels Work for Peptide Delivery
A hydrogel is a three-dimensional network of crosslinked polymers or peptides that absorbs and retains large amounts of water while maintaining structural integrity. The high water content (typically 90-99%) creates an environment compatible with biological molecules: peptides embedded in a hydrogel are surrounded by aqueous solution, not organic solvents, which preserves their native conformation and biological activity.
For peptide delivery, the critical properties are injectability (the gel must flow through a needle), gelation (it must solidify at the target site), and controlled degradation (it must break down at a predictable rate to release the cargo). Several mechanisms can trigger gelation after injection: temperature change (liquid at room temperature, gel at 37 degrees C), pH shift (the body's buffered environment triggers crosslinking), ionic strength (physiological salt concentrations initiate assembly), or enzymatic activity at the injection site.
Self-Assembling Peptide Scaffolds
The most elegant hydrogels for peptide delivery are made from peptides themselves. Short peptide sequences (typically 8-16 amino acids) with alternating hydrophilic and hydrophobic residues spontaneously assemble into beta-sheet nanofibers in aqueous solution. These nanofibers entangle to form a porous gel network that physically traps therapeutic cargo.
Koutsopoulos et al. (2012) used two such self-assembling peptides, (RADA)4 and (KLDL)3, to create layered hydrogel scaffolds.[1] The inner layer, loaded with human immunoglobulin (IgG), was surrounded by an outer layer that acted as a diffusion barrier. Release kinetics depended on peptide concentration, gel thickness, and the layering arrangement. At optimal conditions, the system sustained IgG release for three months. The nanofiber network's pore size (typically 50-200 nm) was small enough to retard diffusion of the large IgG molecules while still allowing their eventual release as the gel gradually dissolved.
Guo et al. (2026) advanced the self-assembling approach by engineering acidic peptide hydrogels with modified N-terminal residues that control assembly mechanism and drug release kinetics.[2] By tuning the N-terminal chemistry, they could adjust the gel's mechanical strength, degradation rate, and interaction with loaded drugs, enabling customized release profiles for different therapeutic applications. This study also addressed a practical limitation: previous self-assembling peptide hydrogels were degraded by pepsin in the gastrointestinal tract, limiting oral applications. The pH-responsive design protected the gel structure in acidic environments.
Temperature-Responsive Hydrogels: Inject as Liquid, Set as Gel
Temperature-responsive (thermoresponsive) hydrogels are among the most clinically practical formulations. They exist as free-flowing solutions at room temperature, allowing easy mixing with peptide cargo and injection through standard needles. Upon reaching body temperature (37 degrees C), they undergo a phase transition to form a solid gel depot at the injection site.
Bai et al. (2026) developed a temperature-responsive hydrogel for delivering antimicrobial peptide-engineered extracellular vesicles to infected wounds.[3] The system achieved sequential release: an initial burst of antimicrobial peptide to control active infection, followed by sustained release of wound-healing factors from the extracellular vesicles. The temperature trigger ensured gelation occurred precisely at the wound site after injection, preventing premature release during preparation or administration.
Bian et al. (2017) created biphenyl-dipeptide supramolecular hydrogels that responded to both temperature and ionic strength, providing dual control over gelation.[4] The dual-responsive design improved the reliability of in situ gelation, since both temperature and the ionic environment of tissue would independently promote gel formation. These gels mimicked the extracellular matrix, making them suitable as both drug delivery vehicles and tissue engineering scaffolds.
Real-World Applications: From Wounds to Eyes
Infected Wound Management
Ba et al. (2026) loaded a self-healing hydrogel with a self-assembling LL-37 derivative for treating infected skin wounds.[5] The "self-healing" property means the gel can reform after being disrupted by mechanical stress (like body movement at the wound site), maintaining continuous contact and sustained peptide release even in challenging anatomical locations. The LL-37 derivative provided antimicrobial activity against wound pathogens while the hydrogel matrix promoted tissue repair, combining two therapeutic functions in a single injectable formulation. This connects to the broader research on how LL-37 disrupts bacterial membranes and biofilms.
Periodontitis Treatment
Chen et al. (2026) developed a charge-complementary hydrogel for sustained release of antimicrobial peptides into periodontal pockets.[6] The gel was formed by mixing two oppositely charged peptide solutions: when the positively charged peptide met the negatively charged peptide, they assembled into a hydrogel through electrostatic interactions. This charge-complementary approach achieved antimicrobial peptide release over 14 or more days, reduced bacterial load in periodontal pockets, and inhibited osteoclast activity that causes the bone loss characteristic of periodontitis. The delivery period matched the treatment interval for periodontal care, potentially eliminating the need for multiple applications.
Ocular Drug Delivery
Durak et al. (2026) addressed one of the most challenging delivery problems in medicine: sustained peptide delivery to the eye.[7] Current anti-VEGF treatments for conditions like macular degeneration require repeated intraocular injections every 4-8 weeks, each carrying risks of endophthalmitis, retinal detachment, and patient discomfort. Their nanoparticle-hydrogel combination system sustained anti-VEGF peptide release in the eye, with the goal of extending the interval between injections. The hydrogel served as a depot that slowly released drug-loaded nanoparticles, which in turn released the anti-VEGF peptide, creating a two-stage sustained release cascade.
Spinal Cord Regeneration
Chen et al. (2026) combined a peptide hydrogel with hydroxyapatite nanorods and neural stem cells for spinal cord injury repair.[8] The hydrogel served triple duty: physically bridging the injury gap, providing sustained release of growth-promoting signals, and creating a three-dimensional scaffold that guided neural stem cell differentiation toward neurons rather than scar-forming glial cells. This application represents the frontier of hydrogel delivery, where the gel is not just a drug carrier but an active component of the therapeutic strategy.
Engineering Release Kinetics: How Slow Is Slow?
The "slow release" in hydrogel delivery ranges from hours to months, depending on the formulation design. Several parameters control the rate:
Mesh size. The pore diameter of the gel network determines how easily cargo molecules can diffuse out. Smaller pores (tighter mesh) mean slower release. Mesh size is controlled by peptide or polymer concentration, crosslink density, and assembly conditions.
Cargo-gel interactions. If the therapeutic peptide carries charges opposite to the gel matrix, electrostatic attraction retains the cargo longer. Hydrophobic interactions between the drug and gel fibers similarly slow release. These affinity-based retention mechanisms add a binding component on top of simple diffusion.
Gel degradation rate. As the hydrogel dissolves through hydrolysis, enzymatic degradation, or simple erosion, it releases trapped cargo. Faster-degrading gels release cargo faster. Gel stability can be tuned through crosslink chemistry, peptide sequence design, and incorporation of protease-resistant modifications.
Layering and compartmentalization. Koutsopoulos's two-layered system demonstrated that surrounding a drug-loaded gel core with a drug-free gel shell dramatically extends release duration by adding a diffusion barrier.[1]
Ahmadi et al. (2026) showed that metal ions can modulate network connectivity in PEG-peptide conjugate hydrogels, providing another tuning parameter.[9] Different metal ions (zinc, copper, nickel) created gels with different mechanical strengths and defect densities, directly affecting how fast cargo could escape the network. This metal-ion tuning approach adds a post-fabrication adjustment mechanism: the same base hydrogel can be made faster- or slower-releasing by changing the crosslinking ion.
Advantages Over Other Delivery Systems
Compared to other peptide delivery platforms, hydrogels offer specific advantages. Unlike liposomal delivery systems that circulate systemically, hydrogels remain localized at the injection site, providing high local concentrations with minimal systemic exposure. This is valuable for applications where the therapeutic target is a specific tissue (wound, joint, eye) rather than a systemic condition.
Unlike microsphere or nanoparticle formulations that require organic solvents during manufacture (potentially denaturing peptide cargo), many hydrogels form under entirely aqueous conditions. Self-assembling peptide hydrogels are particularly gentle: the cargo is mixed into an aqueous peptide solution that gels spontaneously, with no heat, organic solvents, or harsh crosslinking chemicals required. This is important for peptides with complex tertiary structures that would be destroyed by standard encapsulation processes. Proteins like antibodies, growth factors, and cytokines retain their biological activity when loaded into self-assembling peptide hydrogels because they never encounter denaturing conditions.
The self-assembling peptide nanostructure approach takes this further by using the therapeutic peptide itself as the gel-forming material, eliminating the distinction between carrier and cargo entirely.
Hydrogels also offer the advantage of combination delivery. A single gel depot can release multiple therapeutic peptides with different kinetics by exploiting differential cargo-gel interactions. A small, weakly-binding peptide might release quickly for an immediate therapeutic effect, while a larger, strongly-binding peptide releases slowly for sustained maintenance therapy. This sequential release capability, demonstrated in wound healing applications by Bai et al. (2026), is difficult to achieve with other delivery platforms.[3]
Current Limitations
Hydrogel peptide delivery faces several unresolved challenges. Batch-to-batch reproducibility of self-assembling systems depends on peptide purity, concentration accuracy, and assembly conditions. Small variations in pH, temperature, or ionic strength during preparation can alter gel properties and release kinetics. Sterilization of pre-formed hydrogels without disrupting their structure requires careful process development, since standard autoclave conditions would destroy peptide-based gels.
The initial burst release, where a significant fraction of cargo is released in the first hours before the gel fully equilibrates, remains a common problem. Most hydrogel formulations release 20-40% of their cargo in the first 24 hours regardless of the intended sustained-release timeline. This burst occurs because cargo near the gel surface diffuses out before the gel network has fully equilibrated, and because the gelation process itself can transiently create loosely crosslinked regions with large pores. Engineering strategies to reduce this burst (stronger cargo-gel binding, surface coatings, layered architectures) add manufacturing complexity. The two-layered approach used by Koutsopoulos et al. is effective but doubles the preparation steps.
In vivo degradation kinetics are harder to predict than in vitro performance. The injection site's enzymatic environment, blood supply, pH, and mechanical loading all affect how fast the gel degrades. A hydrogel that releases cargo over 30 days in a test tube may last only 10 days in a metabolically active wound bed, or persist for 60 days in an avascular joint space.
Clinical translation has been slow. While hydrogel delivery systems are extensively studied in preclinical models, few have reached clinical trials for peptide delivery specifically. The regulatory pathway for combination products (a drug within a device-like delivery system) adds complexity beyond what a standalone drug requires. Demonstrating long-term biocompatibility at the injection site, predictable in vivo degradation kinetics, and consistent batch manufacturing at commercial scale are all outstanding challenges.
Martin et al. (2020) reviewed the chemical diversity of peptide capping groups used in self-assembling hydrogels, noting that the field has expanded beyond the original Fmoc chemistry to include a wide range of aromatic and non-aromatic modifications that tune assembly properties.[10] This chemical diversity provides a large design space for optimizing hydrogels for specific peptide cargos, but also means that each new formulation requires its own characterization and regulatory evaluation. The connection to exosome-based delivery approaches is worth noting: exosomes embedded in hydrogels combine the targeting specificity of exosomes with the sustained release properties of the gel matrix, a hybrid approach gaining traction in wound healing and regenerative medicine.
The Bottom Line
Injectable hydrogels enable sustained peptide release by trapping therapeutic molecules within self-assembling nanofiber networks, degradable polymer matrices, or temperature-responsive gel depots. Release timelines range from hours to three months depending on mesh size, cargo-gel interactions, degradation rate, and architectural features like layering. Applications span wound care, periodontitis, ocular delivery, and spinal cord regeneration. While preclinical results are strong, clinical translation faces challenges in manufacturing reproducibility, burst release control, sterilization, and combination-product regulatory pathways.